INTRODUCTION

Endovascular treatment has gained an increasing preference for the treatment of complex aortoiliac vascular diseases [1]. Aortobifemoral (ABF) bypass may yield better long-term patency rates but is associated with significant postoperative morbidity (8%-13%; including hemorrhage, sepsis, and heart failure) and mortality (up to 5%) [2-5]. Percutaneous approaches allow for faster patient recovery and shorter inpatient stay. Endovascular intervention is recommended for less complex lesions graded TASC-II class A and B, with comparable short- and medium-term outcomes now being shown for classes C and D [1,6]. Küffer et al. [7] pioneered the kissing stent technique for reconstruction of the aortic bifurcation. During this procedure, stents are placed across both limbs of the common
iliac artery (CIA) and inflated simultaneously. This approach minimizes plaque shift, preserves the native ostia, and reduces distal embolization down the contralateral unaffected limb [8,9]. Concerns remain regarding vessel dissection and thrombosis, particularly in asymptomatic or undiseased limbs [9-12]. The data remains sparse, with many studies hampered by small patient numbers and limited follow up periods [13]. Dated studies have also failed to reflect improvements in outcomes using contemporary stent technology and procedural techniques.

Substantive demand has arisen for viable endovascular alternatives, where surgery is no longer a viable option, such as advanced age and comorbidities. We aimed to review our practice of kissing stents in a tertiary vascular referral center and analyze the outcomes of kissing stents focusing on stent occlusion and complications in which an asymptomatic limb was treated.

This study was reviewed by the West of Scotland NHS Research Ethics Service and a formal ethical review was waived (West of Scotland REC 1 IRB 00002179). The written informed consent was waived by the ethics committee.

**MATERIALS AND METHODS**

The local radiology information system was manually reviewed to identify all aortoiliac intervention cases from January 2015 to November 2020 at our tertiary center. Case records were analyzed to determine whether patients met the inclusion criteria. Patient inclusion was limited to true aortoiliac disease at the bifurcation with involvement of at least one CIA ostium up to 1 cm from the bifurcation, and bilateral kissing intervention (either balloon angioplasty or stent) was performed. All patients underwent endovascular intervention through a multidisciplinary team (MDT) review comprising vascular surgeons and interventional radiologists. The practical criteria for choosing a kissing versus single-stent approach were left to the discretion of the individual teams. In general, a kissing stent approach was selected for complex aortoiliac bifurcation lesions involving the distal aorta and bilateral ostia of CIAs, and asymmetric aortoiliac lesions involving the unilateral CIA ostium, as per the currently accepted best practice.

Fluoroscopic angiographic images were examined by an interventional radiologist to determine the TransAtlantic InterSociety Consensus (TASC) classification. Operative records were reviewed to acquire baseline demographic variables, categorize pre-interventional symptoms according to the Fontaine classification system, and determine if symptoms were unilaterally distributed [14]. Each case record was reviewed longitudinally to determine procedural success, in-hospital complications, and the incidence of late ischemic vascular events defined as recurrent intermittent claudication, stent occlusion, unplanned major amputation, and vascular re-intervention either at the CIA level or more distally. For cases in which intervention was performed on an asymptomatic leg, any subsequent complications to that leg were explored in more qualitative detail.

Vascular access was achieved through bilateral femoral artery punctures, either percutaneously or directly, if the patient underwent concurrent endarterectomy. Lesions were crossed using various methods, either luminal or sub-intimal, but in all cases, luminal re-entry was confirmed prior to treatment, and the lesion was treated from lumen to lumen. The selection of stent type and size was left to the discretion of the interventionalist. Stents were deployed simultaneously to ensure that the vessel flow and ostial integrity were not compromised during contralateral vessel treatment. All patients received maintenance antiplatelet therapy (aspirin 75 mg once daily) for at least one week before the intervention and intra-arterial heparin (50-100 IU/kg) during the procedure. Patients who were already taking clopidogrel before the intervention continued this afterward. All procedures were performed under local anesthesia using vascular closure devices at the end of the procedure. Completion angiography was performed in all cases. Technical success was defined as residual stenosis of ≤30%.

The patients underwent standard clinical follow-up at 3 to 6 months with ankle-brachial pressure index and duplex scan assessments. Further imaging, such as computed tomography angiography, magnetic resonance angiography, or invasive angiography, was performed only if clinical assessment raised suspicion of vessel restenosis or re-occlusion.

Patency was classified as per Society of Vascular Surgery - International Society for Cardiovascular Surgery (SVS-ISCS) Guidelines [15].

**RESULTS**

1) Patient demographics

A total of 106 patients were followed for a median period of 26 months (interquartile range [IQR], 21-51 months). None of the patients was lost to follow-up. The mean age was 66±10 years, with a balanced sex distribution (51% male, 49% female). Cardiovascular comorbidities and risk factors are described in Table 1. Unilateral symptoms were observed in 56 patients (53%). The chief complaints were claudication (60%) and chronic limb-threatening ischemia (CLTI, 40%). Most lesions were classified as either TASC A (49%) or TASC B (41%). In 34 cases (32%), at least one CIA was occluded.
2) Procedural outcomes

Technical success was achieved in 99% of the cases, except in one where a heavily calcified occlusion could not be safely crossed. The procedural mortality rate was 2% due to thoracic aortic dissection and abdominal aortic rupture, and the periprocedural in-hospital complication rate was 9% (Table 2). The 30-day all-cause mortality rate was 3%. Major complications included aortic rupture (two cases) and groin pseudoaneurysm (two cases managed with thrombin injection). A kissing stent strategy was employed in 89 patients (84%), with the remainder being treated with simultaneous balloon angioplasty. The stent diameter ranged from 6 to 10 mm. Balloon-expandable stents were most commonly used in 61 patients (58%), followed by self-expanding stents in 11 patients (10%) for tortuous vessels and covered stents in 17 patients (16%) for more calcified arteries (Table 3). Most patients (73%) were treated with stainless steel stents, and 33 patients (31%) were discharged on the same day of the procedure. None of the patients required conversion to an open surgery.

3) Follow-up outcomes

During the study period, 21 patients (20%) died of cardiovascular and non-cardiovascular causes, with a median period free from recurrent events of 22 months (IQR, 9.6-38). The number of patients free of recurrence-defined peripheral vascular events at 1, 3, and 5 years was 88%, 70%, and 59%, respectively (Fig. 1). Kaplan–Meier analyses of primary and secondary patency rates were 98% and 99%

---

Table 1. Clinical characteristics of kissing stent angioplasty (n=106)

| Clinical characteristic             | Number | Ratio (%) |
|------------------------------------|--------|-----------|
| Sex, male                          | 54     | 51        |
| **Risk factors**                   |        |           |
| Hypertension                       | 54     | 51        |
| Diabetes mellitus                  | 34     | 32        |
| Chronic kidney disease             | 12     | 11        |
| Smoker/ex-smoker                   | 100    | 94        |
| **Pre-interventional Fontaine classification** |        |           |
| II                                 | 64     | 60        |
| III                                | 19     | 18        |
| IV                                 | 23     | 22        |
| **Symptom distribution**           |        |           |
| Unilateral                         | 56     | 53        |
| Bilateral                          | 50     | 47        |
| **Occlusion**                      |        |           |
| Complete occlusion                 | 34     | 32        |
| Stenosis                           | 72     | 68        |
| **TASC-II classification**         |        |           |
| A                                  | 52     | 49        |
| B                                  | 43     | 41        |
| C                                  | 6      | 6         |
| D                                  | 5      | 5         |

TASC, Trans Atlantic Inter-Society Consensus.

Table 2. In-hospital outcomes

| Variable                             | n (%) | Description |
|--------------------------------------|-------|-------------|
| Technical success                    | 105 (99) | -           |
| Cumulative complications             | 9 (9) | -           |
| Intra-procedural complication        | 5 (5) | -           |
| Death                                | 2     | Thoracic aortic dissection, abdominal aortic rupture |
| Vessel dissection                    | 2     | Occlusion of external iliac artery requiring additional stenting |
| Distal embolization                  | 1     | Thrombus in tibioperoneal trunk |
| Post-procedural complication         | 4 (4) | -           |
| Femoral pseudo-aneurysm             | 2     | Requiring thrombin injection |
| Hematoma                             | 1     | Delayed discharge |
| Groin infection                      | 1     | Prolonged in-patient stay and antibiotics |

Table 3. Devices utilized

| Device                                      | Number |
|---------------------------------------------|--------|
| Balloon expandable stent                    | 61     |
| Visipro (Medtronic, Minneapolis, MN, USA)   |        |
| Self expandable stent                       | 9      |
| Smart (Cordis, Miami Lakes, FL, USA)        |        |
| Zilver (Cook Medical, Bloomington, IN, USA) | 2      |
| Covered stent                               |        |
| Advanta (Atrium Medical, Charlotte, NC, USA)| 15     |
| Viabahn (Gore Medical, Flagstaff, AZ, USA)  | 1      |
| VBX (Gore Medical)                          | 1      |
| Balloon only                                | 17     |
at 1 year, 87% and 94% at 3 years, and 85% and 94% at 5 years, respectively (Fig. 1, 2). Six ischemic events occurred in patients with an asymptomatic limb. Review of primary care notes and prescription data did not reveal any lack of compliance with secondary-prevention pharmacotherapy. Three cases were due to late (>30 days) stent thrombosis resulting from aortoiliac intervention (Table 4). One patient presented with unilateral occlusion and underwent ABF grafting at 6 weeks. Two patients presented with bilateral stent occlusion at 4 and 10 months. The former underwent surgical bypass, while the latter was managed conservatively due to comorbidities. The other three ischemic events in the asymptomatic limb were not related to aortoiliac intervention. All patients presented with worsening recurrent claudication due to downstream disease progression in the infrainguinal arteries, requiring surgical or endovascular intervention. Two patients underwent femoropopliteal bypass grafting at 12 and 24 months, and one patient underwent tibial angioplasty. Only one major amputation developed because of the progression of distal infrainguinal disease (Table 5).

**DISCUSSION**

Endovascular therapy is a viable alternative to open surgery for the treatment of aortic bifurcation atherosclerosis. Surgical approaches with ABF grafts continue to carry burdensome in-hospital mortality and morbidity (3%–5% and 8%–13%, respectively) [2,3]. Published longer-term patency rates of ABF were better than those of endovascular therapy (87%–91% at 5 years), but this remains a challenge. To the best of our knowledge, this is the first study to specifically address concerns regarding the durability of this procedure in the unaffected contralateral leg in a substantive patient cohort.

This study demonstrated a low frequency of adverse events in the asymptomatic limbs. No complications occurred in 97% of the patients and in three cases (3%), stent occlusion occurred but did not result in major amputation. When comparing these outcomes with other single-stent intervention studies, Suh et al. [16] reported that non-kissing stent strategies resulted in plaque shift to the undiseased limb, with a similar rate of urgent re-intervention required (3%). To date, only Mohamed et al. [13] provided specific data on asymptomatic contralateral limb complications. They recorded an event rate of 13%, with in-stent restenosis rather than occlusion being predominant. These data remain significantly limited by the small numbers (only 24 patients) and truncated follow-up periods (average of 2 years). While our larger study provides a degree of reassurance with a relatively low recorded number of adverse events, the incidence of stent occlusion emphasizes the ongoing importance of meticulous stent placement, appropriate stent sizing, and use of adjunctive antiplatelet therapy. Other factors, such as poor distal run-off and excessive stent protrusion (>20 mm) into the aorta, are postulated as negative influencers of outcome but remain speculative [17].

Our recorded procedural mortality rate of 2% and early 30 day mortality of 3% were within the range of previous reports (0%–2.3%) [13,18–20]. In our series, post-mortem
Kissing Stents in Aortoiliac Occlusive Disease

analysis revealed that one patient died of thoracic dissection consequent to adrenergic stress rather than wire intervention (the guidewire also did not pass through the affected region of the thoracic aorta during fluoroscopic screening). Another cause of death was due to unrelated sepsis. Complications occurred in 9% of the patients, which is consistent with the literature (0%-12%). In addition, none of the patients required conversion to open surgery. Incidences of procedural complications and occlusion were also similar to those demonstrated for single-vessel iliac intervention, suggesting that the additive risk of placing an additional stent is marginal [21]. Primary patency rates in this study of 98%, 87%, and 85% (at 1, 3, and 5 years, respectively) compare favorably to larger substantive series enrolling >50 patients, such as by Yilmaz et al. (63% at 3 years) [22], Haulon et al. (79% at 3 years) [23], Björses et al. (65% at 5 years) [18], and Vértés et al. (77% at 5 years) [17] and begin to approach those of ABF grafts. These series reported higher reintervention rates of up to 30% compared to our observed 7%.

The TASC lesion distribution was reflective of the current recommended practice; 90% of cases were classified as TASC-II A and B [1]. While this composition may suggest a favorable risk profile, other characteristics in this study group were associated with lesion complexity and poorer primary patency, including 60% CLTI, and 32% had at least one occluded CIA [18]. Although prospective randomized controlled trials comparing endovascular therapy against open surgery are lacking, small retrospective series studies suggest that comparable outcomes can be achieved with stent therapy even for more complex TASC C and D lesions [18,20,24].

Various factors may explain the improvement in procedural and patency outcomes. The routine use of vascular closure devices can reduce the risk of bilateral femoral punctures necessitated by the kissing-stent approach [25]. Newer drug eluting stents theoretically deliver more effective endothelial chemotherapy to dampen neointimal hyperplasia and restenosis, although a consensus on their safety remains pending [26]. Bioabsorbable polymers may further obviate concerns regarding the deployment of a foreign body in asymptomatic vessels [26]. The risk of vessel rupture from intervention in more complex calcified lesions can now be managed through the use of covered stents [27]. As individual and institutional experiences increase, overall proficiency correspondingly develops [28]. This dynamic is optimized by concentrating procedures into high-volume tertiary referral vascular centers.

The strengths of this current study are its large number of patients and long follow-up period. All patients selected for endovascular intervention underwent an MDT review process to reduce selection bias and enhance the applicability to real-world practice. However, while retrospective studies have limitations, our study aimed to provide safety outcome data rather than overturn the existing evidence. There remains a need for high-quality multicenter randomized studies that compare endovascular and surgical techniques across more severe TASC lesion categories.

**CONCLUSION**

Kissing stent deployment is a safe and effective strategy for treating aortoiliac bifurcation diseases. Unfavorable outcomes due to stenting in the asymptomatic iliac artery are very rare. However, long-term surveillance is necessary due to the risk of late thrombosis or downstream disease progression.

Table 4. Recurrent events in asymptomatic leg

| Complication                          | n (%) | TASC classification | Stent type | Diameter (mm) | Outcome                |
|---------------------------------------|-------|---------------------|------------|---------------|-----------------------|
| Related to CIA intervention           | 3 (3) | B                   | Visipro    | 8             | Surgical ABG          |
| Unilateral stent occlusion            | 1     | B                   | Visipro    | 8             | Surgical ABG          |
| Bilateral stent occlusion             | 2     | A                   | Advanta    | 7             | Conservative management |
| Unrelated to CIA intervention        | 3 (3) |                     |            |               |                       |
| Femoral artery disease               | 2     | A                   | Balloon    | 8             | Femoral-popliteal bypass |
| Tibial artery disease                | 1     | A                   |           | 9             | Femoral-popliteal bypass |
|                                       |       |                     | Visipro    | 10            | Tibial artery angioplasty |

CIA, common iliac artery; ABG, aortic-bypass graft.

Table 5. Long term recurrent events

| Complication                        | n (%) | TASC classification | Stent type | Diameter (mm) | Outcome               |
|-------------------------------------|-------|---------------------|------------|---------------|-----------------------|
| Recurrent intermittent claudication | 28 (26)|                     |            |               |                       |
| Stent occlusion                     | 8 (8) |                     | Visipro    | 8             | Surgical ABG          |
| Re-intervention (common iliac artery)| 7 (7) |                     | Advanta    | 7             | Conservative management |
| Re-intervention (leg)               | 11 (10)|                     | Visipro    | 10            |                       |
| Amputation                          | 1 (1) |                     | Visipro    | 10            |                       |

Re-intervention rates of up to 30% compared to our observed 7%.
FUNDING

None.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ORCID

Faheem Asem Ahmad
https://orcid.org/0000-0003-3886-2936

Martin Michael Hennessy
https://orcid.org/0000-0002-9969-0878

Alexander Fredrik Nath
https://orcid.org/0000-0001-7103-1013

AUTHOR CONTRIBUTIONS

Concept and design: FA and MH. Analysis and interpretation: FAA, MMH. Data collection: FAA. Writing the article: FAA. Critical revision of the article: all authors. Final approval of the article: all authors. Statistical analysis: none. Obtained funding: none. Overall responsibility: all authors.

REFERENCES

1) Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). Vasc Med 2015;20:465-478.
2) Bredahl K, Jensen LP, Schroeder TV, Sillesen H, Nielsen H, Eiberg JP. Mortality and complications after aortic bifurcated bypass procedures for chronic aortoiliac occlusive disease. J Vasc Surg 2015;62:75-82.
3) de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. J Vasc Surg 1997;26:558-569.
4) Poulias GE, Doundoulakis N, Prombonas E, Haddad H, Papaioannou K, Lymberiades D, et al. Aorto-femoral bypass and determinants of early success and late favourable outcome. Experience with 1000 consecutive cases. J Cardiovasc Surg (Torino) 1992;33:664-678.
5) Nevelsteen A, Wouters L, Suy R. Aortofemoral dacron reconstruction for aorto-iliac occlusive disease: a 25-year survey. Eur J Vasc Surg 1991;5:179-186.
6) Quan C, Kim DH, Jung HJ, Lee SS. Comparison of results between kissing stent and aortic bifurcated bypass in aortoiliac occlusive disease. Asian J Surg 2020;43:186-192.
7) Küffer G, Spengel F, Steckmeier B. Percutaneous reconstruction of the aortic bifurcation with Palmaz stents: case report. Cardiovasc Interv Radiol 1991;14:170-172.
8) Palmaz JC, Encarnacion CE, Garcia OJ, Schatz RA, Rivera FJ, Laborde JC, et al. Aortic bifurcation stenosis: treatment with intravascular stents. J Vasc Interv Radiol 1991;2:319-323.
9) Tegtmeyer CJ, Kellum CD, Kron IL, Mentzer RM Jr. Percutaneous transluminal angioplasty in the region of the aortic bifurcation. The two-balloon technique with results and long-term follow-up study. Radiology 1985;157:661-665.
10) Insall RL, Loose HW, Chamberlain J. Long-term results of double-balloon percutaneous transluminal angioplasty of the aorta and iliac arteries. Eur J Vasc Surg 1993;7:31-36.
11) Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-2196. Erratum in: Lancet 2013;381:628.
12) Brittenden J, Beattie G, Bradbury AW. Outcome of iliac kissing stents. Eur J Vasc Endovasc Surg 2001;22:466-468.
13) Mohamed F, Sarkar B, Timmons G, Mudawi A, Ashour H, Uherer R. Outcome of “kissing stents” for aortoiliac atherosclerotic disease, including the effect on the non-diseased contralateral iliac limb. Cardiovasc Intervent Radiol 2002;25:472-475.
14) Hardman RL, Jazayeri O, Yi J, Smith M, Gupta R. Overview of classification systems in peripheral artery disease. Semin Intervent Radiol 2014;31:378-388.
15) Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517-538. Erratum in: J Vasc Surg 2000;33:805.
16) Suh Y, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, et al. Outcomes of the single-stent versus kissing-stents technique in asymmetric complex aortoiliac bifurcation lesions. J Vasc Surg 2015;62:68-74.
17) Vértes M, Juhász IZ, Nguyen TD, Veres DS, Hüttl A, Nemes B, et al. Stent protrusion >20 mm into the aorta: a new predictor for restenosis after kissing stent reconstruction of the aortoiliac bifurcation. J Endovasc Ther 2018;25:632-639.
18) Björses K, Ivancev K, Riva L, Manjer J, Uher P, Resch T. Kissing stents in the aortic bifurcation—a valid reconstruction for aorto-iliac occlusive disease. Eur J Vasc Endovasc Surg 2008;36:424-431.

19) Mendelsohn FO, Santos RM, Crowley JJ, Lederman RJ, Cobb FR, Phillips HR, et al. Kissing stents in the aortic bifurcation. Am Heart J 1998;136(4 Pt 1):600-605.

20) Dorigo W, Piffaretti G, Benedetto F, Tarallo A, Castelli P, Spinelli F, et al. A comparison between aortofemoral bypass and aortoiliac kissing stents in patients with complex aortoiliac obstructive disease. J Vasc Surg 2017;65:99-107.

21) Bechter-Hugl B, Falkensammer J, Gorny O, Greiner A, Chemelli A, Freidrich G. The influence of gender on patency rates after iliac artery stenting. J Vasc Surg 2014;59:1588-1596.

22) Yilmaz S, Sindel T, Golbasi I, Turkay C, Mete A, Lüleci E. Aortoiliac kissing stents: long-term results and analysis of risk factors affecting patency. J Endovasc Ther 2006;13:291-301.

23) Haulon S, Mounier-Véhier C, Gaxotte V, Koussa M, Lions C, Haouari BA, et al. Percutaneous reconstruction of the aortoiliac bifurcation with the “kissing stents” technique: long-term follow-up in 106 patients. J Endovasc Ther 2002;9:363-368.

24) Sharafuddin MJ, Hoballah JJ, Kressowik TF, Sharp WJ. Kissing stent reconstruction of the aortoiliac bifurcation. Perspect Vasc Surg Endovasc Ther 2008;20:50-60.

25) Patel R, Muller-Hulsbeck S, Morgan R, Uberoi R. Vascular closure devices in interventional radiology practice. Cardiovasc Intervent Radiol 2015;38:781-793.

26) Brahmbhatt A, Misra S. Techniques in vascular and interventional radiology drug delivery technologies in the superficial femoral artery. Tech Vasc Interv Radiol 2016;19:145-152.

27) Leung DA, Spinosa DJ, Hagspiel KD, Angle JF, Matsumoto AH. Selection of stents for treating iliac arterial occlusive disease. J Vasc Interv Radiol 2003;14(2 Pt 1):137-152.

28) Räder SB, Jørgensen E, Bech B, Lönn L, Ringsted CV. Use of performance curves in estimating number of procedures required to achieve proficiency in coronary angiography. Catheter Cardiovasc Interv 2011;78:387-393.